NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028
RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injuryStudy builds on functional improvements observed in
NervGen started testing a spinal cord injury treatment on real patients. Watch for updates on whether the treatment actually helps people recover hand function.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.